Therapeutic Antibodies – News and Features

Genesis will continue to use HuCAL-based antibodies against the human fibroblast growth factor receptor FGFR5 for target validation and pre-clinical studies for its Zyrogen program.

New agreement to drive the development of OGeS’ own pipeline of antibodies in cancer.

Genmab believes that the introduction of ActivityBase XE into the Hybridoma Discovery department will improve the efficiency of its human antibody screening campaigns.

Dyax will identify therapeutic antibodies for two targets provided by Bayer Schering Pharma.

The program will be implemented in an orthopaedic practice setting during a patient's normal course of treatment, enrolling 80 patients who have been prescribed the blood thinner warfarin.

CENiMED, BioTeZ and Invitek announce their cooperation to develop, produce and market the Recovery-ELISAs for the therapy control of humanized antibodies.

Duke researchers have opened up a new way to screen drugs for possible heart-related side effects and to develop new drugs.

The extended agreement allows Abbott to retain exclusive rights to 10 targets in lung cancer identified by Caprion for up to two years.

Peregrine will provide process development and manufacturing services to support clinical development for Dios' humanized monoclonal antibody to treat thyroid associated disease.

Lonza plans to start large scale production of emerging product class Antibody Drug Conjugates to be utilized primarily in the treatment of cancer.